Reason for request
Indication extension
Summary of opinion
Favourable opinion for reimbursement in the following indication: “KEYTRUDA, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of KEYTRUDA (pembrolizumab), in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is substantial in the indication: “in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
|
Clinical Added Value
| moderate |
Considering:
- demonstration in a randomised, double-blind, phase 3 study (KN-A18 trial, including 56.7% FIGO 2014 stage III - IVA patients) of the superiority of pembrolizumab compared to chemoradiotherapy, for the treatment of FIGO stage IB2-IIB and III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy, in terms of:
- progression-free survival with an HR = 0.70 (95% CI = [0.55; 0.89]; p = 0.002 < the predefined threshold of 0.0172), 7% patients progressed or died in the experimental group versus 29.0% patients in the control group. The median PFS was not reached in either of the two groups.
- overall survival with an HR = 0.67 (95% CI = [0.50; 0.90]; p = 0.0040 < 0.01026), 2% deaths in the experimental group versus 20.5% patients in the control group. The median OS was not reached in either of the two groups.
And despite:
- the absence of any formal conclusion that can be drawn based on the quality of life findings;
- a safety profile deemed to be acceptable compared to chemoradiotherapy but marked by an excess toxicity with grade ≥ 3 AEs reported in 78.3% of patients in the pembrolizumab group and 70.0% of patients in the placebo group). In addition, 20.6% of patients in the pembrolizumab group and 14.9% of patients in the placebo group had an AE resulting in definitive discontinuation of pembrolizumab treatment.
The Committee deems that KEYTRUDA (pembrolizumab) 25 mg/ml, concentrate for solution for infusion, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), provides a moderate clinical added value (CAV III) compared to chemoradiotherapy.
|
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
KezNtKYDFUQc9Ard